Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

A severe lack of early diagnosis coupled with resistance to most available therapeutic
options renders pancreatic cancer as a major clinical concern. The limited efficacy of current …

The use of microRNAs as clinical cancer biomarkers is hindered by the absence of accurate,
fast and inexpensive assays for their detection in biofluids. Here we report a one-step and …

Cancer is a leading cause of death worldwide and cancer incidence and mortality are
rapidly growing. These massive amounts of cancer patients require rapid diagnosis and …

Carcinogenesis involves uncontrolled cell growth, which follows the activation of oncogenes
and/or the deactivation of tumor suppression genes. Metastasis requires down-regulation of …

The transforming growth factor‐beta (TGFβ) superfamily encompasses widespread and
evolutionarily conserved polypeptide growth factors that regulate and orchestrate growth …

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of
cancer related death. It is lethal in nearly all patients, due to an almost complete …

Background Previous studies identified microRNAs (miRNAs) and messenger RNAs with
significantly different expression between normal pancreas and pancreatic cancer (PDAC) …

The most important biological function of exosomes is their possible use as biomarkers in
clinical diagnosis. Compared with biomarkers identified in conventional specimens such as …

Osteosarcoma remains a leading cause of cancer death in adolescents. Treatment
paradigms and survival rates have not improved in two decades. Driving the lack of …